Baseline Characteristics of the ENSEMBLE PLUS Study Population: An Investigation of Shorter Ocrelizumab Infusion Time in Patients with Relapsing-remitting Multiple Sclerosis

Bassem Yamout, Mark Freedman, Carlos Nos, Ludo Vanopdenbosch, Regine Buffels, Karen Kadner, John Mcnamara, Hans-Peter Hartung